Skip to main content

Advertisement

Resistance to new antiretrovirals (ETV, anti-integrases, entry inhibitors)

Article metrics

  • 1208 Accesses

HIV is extremely variable and newly arisen variants may be rapidly selected upon drug pressure. New antivirals are available, new therapeutic options are at hand for all patients, either naïve or multiexperienced. Individualization is the hallmark of new approaches to antiretroviral therapies. Knowledge of drug resistance is important to guide clinicians in devising treatment regimens and to optimally preserve later treatment options for patients.

This presentation will focus on the new technologies, methodologies, models and research tools to enhance detection and interpretation of HIV-1 drug-resistance. Particular attention will be dedicated to the resistance to the new antivirals.

The development of the new second-generation NNRTI etravirine, which has a higher genetic barrier than the first-generation drugs, has led to new understanding of the complexity of NNRTI resistance. To date, 17 mutations have been identified as being associated with etravirine resistance and reduced virological response.

Integrase inhibitors are very potent drugs providing a great opportunity for clinicians, to construct new regimens for individuals with HIV infection resistant to all three traditional classes of antivirals. However, these drugs have a relatively low genetic barrier to resistance and thus require both the selection of an optimised backbone to ensure durable viral suppression and a clear understanding of their residual activity in a failing integrase regimen. Resistance tests able to sequence and detect mutations in integrase are crucial for their proper use in clinical practice.

Viral escape of entry inhibitors may occur through 'classic' viral resistance to the compounds, but also by usage of alternative cell co-receptors. To date the main focus of research on co-receptor antagonists has been on determining and quantifying the CCR5, CXCR4, dual/mixed coreceptor tropism. Recent data begun to emerge on how resistance develops with the accumulation of mutations in gp120 to maraviroc, the first-in-class R5 co-receptor antagonist.

Author information

Correspondence to Francesca Ceccherini-Silberstein.

Rights and permissions

Open Access This article is published under license to BioMed Central Ltd. This is an Open Access article is distributed under the terms of the Creative Commons Attribution 2.0 International License (https://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and Permissions

About this article

Keywords

  • Virological Response
  • Traditional Classis
  • Maraviroc
  • Etravirine
  • Integrase Inhibitor